Current Clinical trials News and Events

Current Clinical trials News and Events, Clinical trials News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 25 | 1000 Results
RASi associated with reduced risk of KRT compared with CCB in CKD patients
In a population-based Swedish database, researchers studied the clinical outcomes of starting renin-angiotensin system inhibitor (RASi) or calcium channel blockers (CCB) in 2,458 patients with CKD G4-5. Compared with CCB, RASi initiation was associated with a lower risk of KRT, but similar risks of mortality and major adverse cardiovascular events. These findings suggest that RASi initiation might slow the progression of kidney disease compared with CCB in patients with advanced CKD, and offer similar cardiovascular protection. (2020-11-24)

Study: TB vaccine linked to lower risk of contracting COVID-19
A widely used tuberculosis vaccine is associated with reduced likelihood of contracting COVID-19 (coronavirus), according to a new study by Cedars-Sinai. The findings raise the possibility that a vaccine already approved by the U.S. Food and Drug Administration may help prevent coronavirus infections or reduce severity of the disease. (2020-11-20)

WHO Guideline Development Group advises against use of remdesivir for covid-19
The antiviral drug remdesivir is not suggested for patients admitted to hospital with covid-19, regardless of how severely ill they are, because there is currently no evidence that it improves survival or the need for ventilation, say a WHO Guideline Development Group (GDG) panel of international experts in The BMJ today. (2020-11-19)

Immunotherapy for lung and other cancers may also be beneficial for rare skin cancer
New research from the University of North Carolina School of Medicine and the Lineberger Comprehensive Cancer Center found immunotherapies effective against lung cancer and melanoma may work against cutaneous angiosarcoma, a rare, highly aggressive skin tumor found primarily on the scalps of older White people. The researchers report tumor-infiltrating lymphocytes and the surface protein markers PD-1 and PD-L1 could help guide the choice of immunotherapy to fight cutaneous angiosarcomas. (2020-11-18)

UTHSC researchers identify three drugs as possible therapeutics for COVID-19
Researchers at the University of Tennessee Health Science Center working with colleagues at the University of New Mexico have identified three drugs, already approved for other uses in humans, as possible therapeutics for COVID-19, the illness caused by the SARS-CoV-2 virus. (2020-11-18)

Comprehensive safety testing of COVID-19 vaccines based on experience with prior vaccines
'The urgent need for COVID-19 vaccines must be balanced with the imperative of ensuring safety and public confidence in vaccines by following the established clinical safety testing protocols throughout vaccine development, including both pre- and post-deployment,' write David M. Knipe and colleagues in this Perspective. (2020-11-17)

Hydroxychloroquine does not help patients hospitalized with COVID-19: Study
Findings from a national study published today in the Journal of the American Medical Association (JAMA) ''do not support'' the use of hydroxychloroquine for the treatment of adult patients hospitalized with COVID-19. (2020-11-13)

Singapore scientists identify potential new biomarker to better personalize cancer therapy
Testing for mutations in RNF43, a protein that affects key cancer cell-growth pathway Wnt, gives clinicians actionable insights to tailor treatments better. (2020-11-13)

Promising MS drug may worsen disease, research suggests
The drug has not yet made it to human trials for multiple sclerosis, but scientists at the University of Virginia School of Medicine are urging their colleagues to move cautiously. (2020-11-13)

Approved JAK inhibitor baricitinib shows promise against cytokine storm in COVID-19 clinical study
A clinical study involving 601 patients in Italy and Spain suggests that the JAK inhibitor drug baricitinib may enhance survival rates of patients (2020-11-13)

Rare angiosarcoma tumors respond well to immunotherapy combination
Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute's (NCI) Division of Cancer Diagnosis and Treatment (DCTD), part of the National Institutes of Health, have shown that the immunotherapy combination of ipilimumab and nivolumab shrinks rare angiosarcoma tumors in 25 percent of all patients, with some having an even stronger response to the drug combination. (2020-11-13)

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic. (2020-11-12)

JAMA reports fluvoxamine as potential early treatment for COVID-19
The COVID-19 Early Treatment Fund (CETF) announced that JAMA, The Journal of the American Medical Association, published the results of a Washington University School of Medicine in St. Louis double-blind, randomized controlled clinical trial that investigated whether the antidepressant medication fluvoxamine can reduce the risk for respiratory deterioration. (2020-11-12)

Not all patients with certain type of heart attack receive the same care
An analysis of medical records reveals variability in the tests and treatments that patients with type 2 myocardial infarction receive during and after their hospital stay. Clinical trials are needed to provide guidance to physicians on how to best care for these patients. (2020-11-11)

Potential brain damage marker could guide assessment and treatment of strokes
A team of researchers has discovered that a protein found in the nervous system can predict the severity of brain damage and long-term outcomes in patients who have suffered a stroke. (2020-11-11)

Protein in blood may predict prognosis, recovery from stroke
Researchers at Mayo Clinic in Florida and collaborators have found that a biomarker in the blood may determine the extent of brain injury from different types of strokes and predict prognosis in these patients. Their findings are reported in Science Translational Medicine. (2020-11-11)

As cancer has evolved, it is time for cancer research to do the same
Marking Lung Cancer Awareness month, a new study investigates the extent to which human-based, non-animal approaches are supplanting animal models in cancer research - comparing number of publications, funding, and publications associated with clinical trials between xenograft models and human organoids. The analysis reveals limited support for human biology-based methods and the authors recommend encouraging efforts to reduce reliance on animal testing in order to accelerate discovery and development of new, effective and affordable medicines. (2020-11-10)

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening. Researchers at the University of Georgia analyzed the health outcomes of 90,275 patients, comparing those who were screened versus those who received usual medical care or chest x-rays. (2020-11-10)

$1 million to support manufacturing of COVID-19 treatments, vaccines at uOttawa, Ottawa Hospital
Researchers from the University of Ottawa and The Ottawa Hospital have been awarded $1,050,000 million from the Canada Foundation for Innovation to support facilities for manufacturing innovative treatments and vaccines for COVID-19. (2020-11-09)

Could SARS-CoV-2 evolve resistance to COVID-19 vaccines?
Similar to bacteria evolving resistance to antibiotics, viruses can evolve resistance to vaccines, and the evolution of SARS-CoV-2 could undermine the effectiveness of vaccines that are currently under development, according to a paper published November 9 in the open-access journal PLOS Biology by David Kennedy and Andrew Read from Pennsylvania State University, USA. The authors also offer recommendations to vaccine developers for minimizing the likelihood of this outcome. (2020-11-09)

Researchers identify key marker to help speed development of CMV vaccines
A Duke Health-led research team has identified a key marker that will help speed effective vaccine designs for cytomegalovirus (CMV), the most common congenital infection worldwide and a leading cause of infant brain damage. (2020-11-04)

Cancer treatment could be replicated for COVID-19
Beta-blockers could potentially be used to treat COVID-19, according to a new international study by Italian and Australian scientists. (2020-11-02)

The Lancet Infectious Diseases: Experts outline key challenges for assessing clinical efficacy of COVID-19 vaccines
Collaboration and standardised approaches for assessing different vaccine efficacy endpoints are key for meaningful comparison of different COVID-19 vaccine candidates to ensure that the most effective vaccines are deployed, say authors of an opinion piece based on a review of evidence, and published in The Lancet Infectious Diseases journal. (2020-10-27)

MFS Is a strong surrogate endpoint for OS for men receiving salvage RT for recurrent prostate cancer
An analysis of the phase III NRG Oncology clinical trial RTOG 9601 on men receiving salvage radiotherapy (SRT) following prostatectomy for recurrent prostate cancer indicated that, while biochemical failure (BF) was not a strong surrogate endpoint to determine overall survival (OS), metastasis-free survival (MFS) was in this patient population. (2020-10-26)

Effectiveness of gemcitabine & daily RT for bladder preservation in muscle-invasive bladder cancer
Bladder preservation with trimodality therapy can be a safe and effective alternative to cystectomy for selected patients with muscle-invasive bladder cancer. The phase II NRG Oncology NRG-RTOG 0712 trial evaluated two regimens. One was the prior RTOG standard using 5-flourouracil and cisplatin with twice daily radiation (FCT), and the other a regimen of gemcitabine and daily radiation (GD) which had demonstrated efficacy in single institution clinical trials. (2020-10-26)

New test method to standardize immunological evaluation of nucleic acid nanoparticles
Recent successes of several FDA-approved therapeutic nucleic acids, together with the rapid preclinical progression of nucleic acid nanoparticles (NANPs), have made it apparent that immunological effects of NANPs must be carefully assessed to permit their successful clinical translation. Based on extensive studies, a standardized protocol allowing for the assessment of NANPs' pro-inflammatory properties in validated preclinical model, peripheral blood mononuclear cells, has been developed to be highly predictive of cytokine responses. (2020-10-23)

Diagnosing Parkinson's disease with skin samples could lead to earlier detection
New research shows a simple skin test can accurately identify Parkinson's disease, which could lead to earlier detection of the disease and better outcomes for patients. Currently, Parkinson's disease is diagnosed by clinical signs and symptoms but only definitively diagnosed at autopsy. The researchers conducted a blinded study of 50 skin samples using an assay originally designed to detect mad cow disease. (2020-10-21)

Perspective: Understanding COVID-19 vaccine efficacy
In this Perspective, Marc Lipsitch and Natalie Dean consider what would happen if a COVID-19 vaccine offers little to no protection in high-risk groups, like the elderly and those with comorbidities, yet is able to reduce infection or infectiousness in younger adults. (2020-10-21)

Existing heart drugs may help cancer patients respond better to PD(L)1 immunotherapy
Researchers have found that a class of commonly-used heart drugs may also improve patients' responses to anti-cancer immunotherapies called PD(L)1 inhibitors, according to preliminary findings to be presented at the 32th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, which is taking place online. (2020-10-21)

Covid-19 vaccine trials cannot tell us if they will save lives
Vaccines are being hailed as the solution to the covid-19 pandemic, but the vaccine trials currently underway are not designed to tell us if they will save lives, reports Peter Doshi, Associate Editor at The BMJ today. (2020-10-21)

Cannabis reduces OCD symptoms by half in the short-term
People with obsessive-compulsive disorder (OCD) report that the severity of symptoms was reduced by about half within four hours of smoking cannabis. After smoking cannabis, users with OCD reported it reduced their compulsions by 60%, intrusions, or unwanted thoughts, by 49% and anxiety by 52%. The study also found that higher doses and cannabis with higher concentrations of CBD were associated with larger reductions in compulsions. (2020-10-20)

Mammography screening saves lives also in older age
Mammography, which is an x-ray picture of the breast, is efficient also for women over the age of 70. For women invited to regular mammography screening over the age of 70, the reduction in mortality rate was significant. This according to a vast new study from Sweden. (2020-10-20)

Penn Medicine researchers use artificial intelligence to 'redefine' Alzheimer's Disease
The researchers will apply advanced artificial intelligence (AI) methods to integrate and find patterns in genetic, imaging, and clinical data from over 60,000 Alzheimer's patients -- representing one of the largest and most ambitious research undertakings of its kind. (2020-10-14)

As genome-editing trials become more common, informed consent is changing
As public interest and expanded research in human genome editing grows, many questions remain about ethical, legal and social implications of the technology. People who are seriously ill may overestimate the benefits of early clinical trials while underestimating the risks. This makes properly understanding informed consent, the full knowledge of risks and benefits of treatments, especially important. (2020-10-12)

Revised clinical trial rules during COVID-19 pandemic may benefit patients, survey shows
The COVID-19 pandemic has led to new rules and expectations for clinical trials. Following guidance from federal agencies, institutions such as UT Southwestern adjusted clinical trial operations. To protect patient safety, changes such as utilizing remote consents, conducting telehealth study visits, and shipping oral study treatment to patients' homes have streamlined the clinical trial participation process. (2020-10-08)

Barriers and facilitators for social distancing recommendations during COVID-19
Survey of North Americans and Europeans examines motivations and barriers for social distancing; finds men and young people relatively less likely to comply (2020-10-07)

Sensory device stimulates ears and tongue to treat tinnitus in large trial
A device that stimulates the ears and tongue substantially reduced the severity of tinnitus symptoms in 326 patients for as long as 1 year, while achieving high patient satisfaction and adherence. (2020-10-07)

Preliminary results of two large immune therapy studies show promise in advanced cervical cancer
COLUMBUS, Ohio - Preliminary results from two independent, phase II clinical trials investigating a new PD-1 (programmed cell death protein 1)-based immune therapy for metastatic cervical cancer suggest potential new treatment options for a disease that currently has limited effective options and disproportionately impacts younger women. (2020-10-05)

Lab grown tumour models could lead to improved ovarian cancer treatments
Scientists have created a three-dimensional (3D) tumour model in the laboratory for ovarian cancer that could lead to improved understanding and treatment of the disease. (2020-10-02)

Study details strategies to address barriers keeping older adults out of clinical trials
A study revealed little effort has been made to improve older adult representation in clinical trials of new cancer drugs, even when the treatment is aimed at a disease that disproportionately affects this age group. ''There is currently no incentive to establish real-world effectiveness among older adults. Older adults need a seat at the table,'' said Dr. Mina Sedrak, lead author, adding 2 in 5 Americans with cancer are age 70 or older. (2020-10-01)

Page 1 of 25 | 1000 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.